Medical Device Penetration Testing for NeuroTech & BCIs
Penetration testing for BCIs, neurostimulators, DBS, and closed-loop neuromodulation. Implant RF, programmer trust, and patient-app exposure tested.
Last reviewed March 2026 · Reviewed against the FDA Feb 3, 2026 final premarket cybersecurity guidance.
NeuroTechnology devices - BCIs, DBS systems, spinal cord stimulators, closed-loop neuromodulation - pair the regulatory weight of a Class III implant with the consumer-app exposure of a wearable. A compromise of stimulation parameters can affect motor control, mood, or cognition directly. Pen testing for this segment is necessarily a system-of-systems test: implant ↔ clinician programmer, implant ↔ patient remote, programmer ↔ cloud, and the closed-loop path inside the implant itself.
We analyze the wireless link to the implant - typically MICS, BLE, or a proprietary RF profile - for pairing strength, session uniqueness, and whether stimulation-parameter writes are gated by an additional clinician-presence factor. We exercise the clinician programmer (often a hardened tablet) for credential storage, session timeout, and whether a stolen programmer is meaningfully different from a stolen consumer phone (it usually isn't, by default). On the patient side we test the consumer companion app the way an attacker would: rooted device, instrumented runtime, MITM with pinned certs bypassed - looking for whether the implant collapses to trusting the app's view of the world. For closed-loop systems we audit the sensing-to-stimulation control integrity: can a spoofed neural signal drive the actuator, and what's the fail-safe if the sense path is suppressed? Reports are framed as risk-control evidence the regulatory team can take into a Q-Sub conversation.
Layers we exercise in this engagement
The neurotech / bci system, from the outermost cloud and clinician surfaces down to the device itself. Highlighted layers are exercised by this medical device penetration testing.
- 01Cloud APIs Tested
- 02Patient remote Tested
- 03Clinician programmer Tested
- 04BLE / MICS / proprietary RF Tested
- 05Implant firmware Tested
- 06Closed-loop sensing Tested
Layers shown outermost (top) to innermost (bottom). Dashed rows are part of the surrounding system but out of scope for this view.
Medical Device Penetration Testing engagement, end to end
Four phases, fixed fee, scoped to neurotech / bci architecture from kickoff onward.
-
01
Scope + kickoff
Architecture review, attack-surface walkthrough, and threat-model alignment with your team. Written scope in 24 hours.
-
02
Threat-model alignment
Every STRIDE entry in your threat model is matched to a planned test case so reviewers see one-to-one coverage.
-
03
Test execution
Device, cloud, mobile, BLE/RF, and OTA channels exercised in parallel by senior engineers - not a single web-app scan.
-
04
Reviewer-ready report + retest
eSTAR-format report with findings, CVSS, remediation, and unlimited retests until every finding is closed.
What we see in NeuroTech / BCI medical device penetration testing
The patterns we hit in this segment, this service, again and again.
-
Stimulation parameter write lacks clinician-presence factor
Once paired, programmer can change pulse width / amplitude without re-authenticating. Stolen-programmer scenario is not modeled in the threat file.
-
Patient-app companion shares HMAC key across all implants of model
Reverse-engineered companion app contained a single HMAC key used to sign implant commands. Compromise of one app = forged commands to any device of the model.
-
Closed-loop sense channel un-authenticated
Internal sensing path between sense electrodes and stim controller has no integrity check. Bench fault-injection on the sense ADC drives unintended stimulation.
-
Cloud-side device registry permits cross-clinic enumeration
Authenticated clinician account can list devices outside their assigned clinic via predictable enumeration on the registry endpoint.
Public neurotech / bci cybersecurity history
Recalls, CISA ICS-MA advisories, and disclosed research that shape what reviewers ask about in this segment - and what our scope is built to cover.
"Blue Goat's niche expertise in FDA-facing cybersecurity made all the difference. Their reports were built with the FDA's expectations in mind - it gave us confidence that we were submitting exactly what reviewers want to see."
Standard Medical Device Penetration Testing deliverables
The same deliverables the parent Medical Device Penetration Testing service ships with - tuned to your neurotech / bci architecture.
- Device, firmware, and embedded testing - hardware teardown, JTAG/UART/SPI bus access, firmware extraction and reverse engineering, and exploitation of the secure boot, debug, and update paths. Done by operators who have tested infusion pumps, monitors, surgical robots, and implantables.
- Companion app and cloud API coverage - iOS/Android binary analysis, BLE pairing/GATT attacks, REST/MQTT/gRPC fuzzing, authentication and authorization testing, and tenant-isolation checks. We test the device as patients and clinicians actually use it, not in isolation.
- FDA-ready penetration test reports - executive summary, methodology, CVSS-scored findings tied to your threat model, reproduction steps, and a Letter of Attestation formatted to the FDA's 2026 premarket guidance. Reviewer-ready, not a generic IT security PDF.
- Remediation guidance and re-test included - written fix recommendations per finding, engineer-to-engineer support during remediation, and unlimited re-tests of fixed issues inside the fixed fee. You leave with a clean report, not a list of open items.
What lands in your eSTAR submission
Reviewer-format documents ready to drop straight into the cybersecurity attachments of your submission - no reformatting on your side.
- Device, firmware, and embedded testing - hardware teardown, JTAG/UART/SPI bus access, firmware extraction and reverse engineering, and exploitation of the secure boot, debug, and update paths. Done by operators who have tested infusion pumps, monitors, surgical robots, and implantables.
- Companion app and cloud API coverage - iOS/Android binary analysis, BLE pairing/GATT attacks, REST/MQTT/gRPC fuzzing, authentication and authorization testing, and tenant-isolation checks. We test the device as patients and clinicians actually use it, not in isolation.
- FDA-ready penetration test reports - executive summary, methodology, CVSS-scored findings tied to your threat model, reproduction steps, and a Letter of Attestation formatted to the FDA's 2026 premarket guidance. Reviewer-ready, not a generic IT security PDF.
- Remediation guidance and re-test included - written fix recommendations per finding, engineer-to-engineer support during remediation, and unlimited re-tests of fixed issues inside the fixed fee. You leave with a clean report, not a list of open items.
Standards that apply
The NeuroTech / BCI baseline, plus the call-outs that matter for medical device penetration testing in this segment.
Segment-specific call-outs
IEC 60601-2-10 / -2-40 (electrical stim) + ANSI/AAMI SW96
Cyber findings on stim parameters are essential-performance impacts. Risk-control treatment must reflect that, not be relegated to annex IT considerations.
AAMI TIR97 (postmarket cybersecurity for Class III implants)
Implant lifetimes (5-15 years) make the postmarket plan part of the premarket package. We test what's deployed AND what the update path looks like.
What's not in scope
We scope tightly on purpose. These items are either out-of-scope by design or belong in a separate engagement - we'll tell you up front, not after kickoff.
- Hospital enterprise IT network penetration testing
- Clinical efficacy or human-factors validation
- Physical security of manufacturing sites
- Source-code review (unless explicitly added as a separate engagement)
Medical Device Penetration Testing for NeuroTech / BCI - FAQs
The questions buyers in this segment actually ask before scoping a medical device penetration testing engagement.
Go deeper on NeuroTech / BCI and premarket
A practical, ungated buyer's guide for medical device manufacturers evaluating cybersecurity partners, what goes wrong, why it costs you, and what to demand from your next engagement. Aligned to the FDA February 2026 premarket guidance.
The most common high- and critical-severity findings we surface in medical device penetration tests, what each one looks like in the field, and how to fix it before your FDA submission.
A practical, ungated guide to the threat modeling gaps that trigger FDA cybersecurity questions in 510(k), De Novo, and PMA submissions - and exactly how to close them before reviewers find them.
What happens if you fail an FDA cybersecurity inspection: the 483-to-consent-decree enforcement ladder and the commercial fallout for device makers.
FDA Section 524B applies to any new premarket submission for a cyber device, including legacy platforms. What attaches, what postmarket rules cover the rest.
SPDF vs SSDLC for medical devices. Why the FDA's Secure Product Development Framework demands more than a standard Secure SDLC, and what to add.
Other engagements for NeuroTech / BCI
Teams in this segment commonly bundle these alongside medical device penetration testing.
Keep going
Scope a Medical Device Penetration Testing engagement for your neurotech / bci program.
A 30-minute call with a senior engineer who has done this in neurotech / bci before - not a sales rep.